BSI coordinates EU project
Budapest/Evry – The European Commission has awarded a a2.9 million grant to the COBRED consortium, which is coordinated by the French-Hungarian biotech company BioSystems International (BSI).
Over the next three years, COBRED (www.cobred.eu) will be working on finding colon cancer and breast cancer biomarkers (metabolites, proteins, PBL derived mRNAs), particularly for the detection and assessment of the status of minimal residual disease, metastases, and recurrences following surgery and chemotherapy and for patient follow-up through the use of three high throughput technologies. In addition to BioSystems International, the consortium is comprised of two other biotechnology firms (Ipsogen, Marseille, France; Biocrates, Innsbruck, Austria), two large cancer centres (Institut Curie , Paris; Institut Gustave Roussy, Villejuif, both France) and three academic institutions (University of Debrecen, Hungary; University of Innsbruck, Austria; University of Tartu, Estonia). The consultancy firm Arttic (Paris, France) will support the consortium with project management.
COBRED aims to deliver a set of biomarker candidates verified in preclinical studies for large scale clinical testing and for further commercial development. Furthermore, COBRED will demonstrate the potential for exploring the consolidated data that results from genomics, mass spectrometry and proteomics technologies as well as clinical profiles with advanced data mining technologies for enhanced biomarker discovery. Data gathered in the study may point to cancer mechanisms that are currently not sufficiently described.
Dr. Laszlo Takacs, CSO of BioSystems International and COBRED Project Coordinator, said: “This unprecedented project has the power to discover new cancer diagnostics. I am happy to see the enthusiasm of participating clinicians at the cancer centres and of scientists at the academic and industrial laboratories.”B